Navigation Links
Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
Date:11/21/2008

er major companies.

Based on our transforming scientific discoveries and sound business model, Intellect is on track to become a major player in the discovery and development of drugs to treat AD, a devastating disease that is rapidly growing in prevalence and for which there are currently no efficacious disease-modifying treatments. We have made excellent progress towards achieving our goal for our company even in the face of a truly daunting financial market.

Financially, we continue to vigorously pursue various options to provide the funding necessary to fully realize the aforementioned strategy. We thank you for your patience and understanding as we go through this process.

As we move forward to realize the potential of our discoveries, we are grateful for the support and confidence of all of our shareholders. Be assured that we are steadfast in the pursuit of our goal to build a company that makes significant contributions to the public health and that brings outstanding financial rewards to its investors.

Thank you for your continued interest and support of Intellect Neurosciences, as we work to develop new drugs aimed at slowing or preventing Alzheimer's disease.

Sincerely,

Daniel Chain, Ph.D.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of AD and other disorders. The Company has a broad proprietary immunotherapy platform for both passive and active immunization against AD. Also, Intellect has completed Phase I clinical trials for OXIGON(R), which has the potential to be used as a treatment for AD and other serious disorders.

For additional information, please visit
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
10. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
11. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Sensors market is estimated at $0.19 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... SYDNEY , Aug. 31, 2015  US-Australian ... NVGN ) today confirmed its comprehensive scientific ... ground-breaking technology platforms in areas of unmet patient ... through the remaining preclinical projects prior to entering ... lead compounds. Acting Chief Executive Officer, ...
(Date:8/31/2015)... Grove, IL (PRWEB) , ... August 31, 2015 ... ... impurities (PGIs), as a high priority in the drug development approval process. Thus, ... , This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Global & USA BioSimilar Market Analysis ... The highly awaited US Biosimilar market will be initiated ... biologic, Zarxio. How will the global market react? Will ... that biosimilars could save the US economy up to ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... 14 at 8:00 a.m. PDT ... ... (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing products targeting the ... December 31, 2007., "Our achievements in 2007 have advanced our partnered ...
... (NASDAQ: ANPI , TSX: ANP), a global ... filing of its audited,consolidated financial statements and Management,s ... 2007 and the restatement of its audited,consolidated financial ... For the year ended December 31, 2007, ...
... CORONA, Calif., March 13 Watson,Pharmaceuticals, Inc. ... today confirmed that it has filed an Abbreviated ... Drug Administration (FDA) seeking,approval to market its Levonorgestrel ... oral contraceptive product prior to the,expiration of patents ...
Cached Biology Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 2Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 3Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 4Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 5Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 6Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 7Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 8Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 9Watson Files FDA Application for Generic LYBREL(R) 2
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
(Date:8/17/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 2015. The new marketing campaign is being spearheaded by ... Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... retail driven marketing and brand awareness and has a ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a prominent smartphone manufacturer in ... selected FPC1 155 for ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... Picture two charged particles in a vacuum. Thanks to ... force these particles exert upon one another, and therefore ... simple medium say, water and the calculation ... water, which in turn may slow, speed, or otherwise ...
... the unique aroma signature of the durian revered as ... as the world,s foulest smelling food has uncovered several ... in ACS, Journal of Agricultural and Food Chemistry . ... Asian food shops in the United States and elsewhere, has ...
... believe that fish ear bones and their distinctive growth rings ... in aquatic environments., The earbones, or ,otoliths, help fish to ... set down annual growth rings that can be measured and ... "Otoliths can form the basis of new techniques for ...
Cached Biology News:Outside a vacuum: Model predicts movement of charged particles in complex media 2Fish ear bones point to climate impacts 2
... The Beacon 2000 Fluorescence Polarization System ... research and assay development. Standard Beacon ... 2000 System uses a quartz-halogen lamp ... of 360-700 nm. It accommodates all ...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... buffer, pH 10.2 give activity approx. 2X ... in diethanolamine buffer, pH 9.8 give activity ... system. Protein determined by Biuret Physical form: ... Unit Definition: One unit will hydrolyze 1 ...
... traps a wide variety of solvent vapors that can ... flask (GCF400) allows for the collection of liquid into ... time minimizes waiting period., Ultra low -104 ... , Digital Display of ...
Biology Products: